Biomarin Pharmaceutical (BMRN) Short term Debt (2012 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Short term Debt came in at $494.8 million in Q2 2024, little changed on a QoQ basis from $494.4 million in Q1 2024.
Biomarin Pharmaceutical (BMRN) Short term Debt (2012 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 12 years of Short term Debt data on file, last reported at $494.8 million in Q2 2024.
- Quarterly Short term Debt changed N/A year-over-year to $494.8 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $494.8 million (changed N/A YoY) and the FY2023 annual result came in at $493.9 million, up 3001.27% from the prior year.
- Short term Debt held at $494.8 million in Q2 2024, from $494.4 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $494.8 million in Q2 2024 to a low of $15.9 million in Q4 2022.
- A 5-year average of $206.5 million and a median of $56.1 million in 2021 frame the typical range for Short term Debt.
- Annual changes were most pronounced in 2020 — Short term Debt jumped 3642.9% — and 2021, when it sank 91.58%.
- Tracing BMRN's Short term Debt over 5 years: stood at $374.3 million in 2020, then sank by 87.11% to $48.2 million in 2021, then slumped by 66.98% to $15.9 million in 2022, then surged by 3001.27% to $493.9 million in 2023, then increased by 0.19% to $494.8 million in 2024.
- The last three Short term Debt figures came in at $494.8 million (Q2 2024), $494.4 million (Q1 2024), and $493.9 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 658.20 Mn |
| Jun 30, 2024 | 494.84 Mn |
| Mar 31, 2024 | 494.36 Mn |
| Dec 31, 2023 | 493.88 Mn |
| Dec 31, 2022 | 15.93 Mn |
| Sep 30, 2022 | 28.30 Mn |
| Jun 30, 2022 | 29.95 Mn |
| Mar 31, 2022 | 64.00 Mn |
| Dec 31, 2021 | 48.23 Mn |
| Sep 30, 2021 | 48.20 Mn |
| Jun 30, 2021 | 32.20 Mn |
| Mar 31, 2021 | 30.81 Mn |
| Sep 30, 2020 | 374.29 Mn |
| Jun 30, 2020 | 370.10 Mn |
| Mar 31, 2020 | 365.96 Mn |
| Dec 31, 2019 | 361.88 Mn |
| Sep 30, 2019 | 10.00 Mn |
| Jun 30, 2019 | 9.93 Mn |
| Mar 31, 2019 | 88.16 Mn |
| Dec 31, 2018 | 85.95 Mn |